Leveraging Real-World Evidence to Enhance Clinical Trials
Authors:
- 19 June 2024
- journal article
- editorial
- Published by Elsevier in Ophthalmology
- Vol. 131 (7) , 756-758
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Prevalence of Diabetic Retinopathy in the US in 2021JAMA Ophthalmology, 2023
- Representation Matters—Diversity in Retina Clinical TrialsJAMA Ophthalmology, 2022
- Representation of Race and Ethnicity in Randomized Clinical Trials of Diabetic Macular Edema and Retinal Vein Occlusion Compared to 2010 US Census DataJAMA Ophthalmology, 2022
- Trends in Prevalence and Treatment of Diabetic Macular Edema and Vision-Threatening Diabetic Retinopathy Among Medicare Part B Fee-for-Service BeneficiariesJAMA Ophthalmology, 2022
- Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular DegenerationJAMA Ophthalmology, 2021
- Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic RetinopathyJAMA Ophthalmology, 2021
- Effect of Intravitreous Anti–Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic RetinopathyJAMA Ophthalmology, 2021
- Racial and Ethnic Disparities in Primary Open-Angle Glaucoma Clinical TrialsJAMA Network Open, 2021
- Prevalence of Age-Related Macular Degeneration in the US PopulationArchives of Ophthalmology (1950), 2011
- Prevalence of Age-Related Maculopathy in Older EuropeansArchives of Ophthalmology (1950), 2006